PHARNEXT: After 6 years of total trial time, data from the open-label PLEO-CMT-FU trial are consistent with a long-term benefit of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)

New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on

Related Keywords

Schwann ,Baden Wüberg ,Germany ,Canada ,United States ,Paris ,France General ,France ,Gewinn Nur ,Fabreguettes Leib ,Shahram Attarian ,Schwartz ,Neuromuscular Diseases Reference Centers ,Rare Diseases Network ,University Hospital La Timone ,Open Label Phase ,Overall Neuropathy Limitation Scale ,Charcot Marie Tooth Disease Type ,Overall Neuropathy Limitations Scale ,Neuromuscular Diseases ,Diseases Network ,Lead Investigator ,First Double Blind Phase ,Open Label Extension ,Total Trial ,High Dose ,Low Dose ,Label Extension ,Meter Walk Test ,Quantified Muscular Testing ,Patient Global Impression ,Charcot Marie Tooth Neuropathy Score ,Euronext Growth ,Presse Financi ,Pharnext ,After ,Tears ,Total ,Trial ,Dime ,Data ,Rom ,Pen ,Label ,Leo ,Consistent ,Song ,Term ,Benefit ,Xt3003 ,Charcot ,Marie ,Tooth ,Disease ,Type ,Mt1a ,